Probiotics for ventilator-associated pneumonia the need for a large, multicenter, randomized controlled trial

Chest

Volumn 143, Issue 3, 2013, Pages 590-592

  Boyer, Anthony F ^a   Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

ALGORITHM; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BACTEREMIA; CRITICALLY ILL PATIENT; EDITORIAL; ENDOCARDITIS; HEALTH SURVEY; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INFECTION PREVENTION; INTESTINE ISCHEMIA; LENGTH OF STAY; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84874962328     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2139     Document Type: Editorial

References (21)

1. Bouadma L, Wolff M, Lucet JC. Ventilator-associated pneumonia and its prevention. Curr Opin Infect Dis. 2012; 25 (4): 395-404.
2. Bekaert M, Timsit JF, Vansteelandt S, et al Outcomerea Study Group. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med. 2011; 184 (10): 1133-1139.
3. Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med. 2011; 39 (12): 2736-2742.
4. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002; 165 (7): 867-903.
5. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator- associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol. 2012; 33 (3): 250-256.
6. Skrupky LP, McConnell K, Dallas J, Kollef MH. A comparison of ventilator-associated pneumonia rates as identified according to the National Healthcare Safety Network and American College of Chest Physicians criteria. Crit Care Med. 2012; 40 (1): 281-284.
7. Klompas M, Khan Y, Kleinman K, et al CDC Prevention Epicenters Program. Multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation. PLoS ONE. 2011; 6 (3): e18062.
8. Kollef MH. Prevention of ventilator-associated pneumonia or ventilator-associated complications: a worthy, yet challenging, goal. Crit Care Med. 2012; 40 (1): 271-277.
9. Chung DR, Song JH, Kim SH, et al Asian Network for Surveillance of Resistant Pathogens Study Group. High prevalence of multidrug-resistant nonfermenters in hospitalacquired pneumonia in Asia. Am J Respir Crit Care Med. 2011; 184 (12): 1409-1417.
10. Joint Food and Agriculture Organization/World Health Organization Working Group. Guidelines for the evaluation of probiotics in food: report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. London, ON, Canada; 2002. World Health Organization website. http ://www. who. int /foodsafety /fs-management /en /probiotic-guidelines. pdf. Accessed September 4, 2012.
11. Ghosh S, van Heel D, Playford RJ. Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut. 2004; 53 (5): 620-622.
12. McNaught CE, Woodcock NP, MacFie J, Mitchell CJ. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut. 2002; 51 (6): 827-831.
13. van der Kleij D, Latz E, Brouwers JF, et al. A novel hostparasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem. 2002; 277 (50): 48122-48129.
14. Chapat L, Chemin K, Dubois B, Bourdet-Sicard R, Kaiserlian D. Lactobacillus casei reduces CD8 1 T cellmediated skin inflammation. Eur J Immunol. 2004; 34 (9): 2520-2528.
15. Isolauri E, Sütas Y, Kankaanpää P, Arvilommi H, Salminen S. Probiotics: effects on immunity. Am J Clin Nutr. 2001; 73 (suppl 2): 444S - 450S.
16. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis. 2008; 46 (suppl 2): S87 - S91.
17. Besselink MG, van Santvoort HC, Buskens E, et al Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371 (9613): 651-659.
18. Snydman DR. The safety of probiotics. Clin Infect Dis. 2008; 46 (suppl 2): S104 - S111.
19. Barraud D, Bollaert P-E, Gibot S. Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials. Chest. 2013; 143 (3): 646-655.
20. Liu KX, Zhu YG, Zhang J, et al. Probiotics' effects on the incidence of nosocomial pneumonia in critically ill patients: a systematic review and meta-analysis. Crit Care. 2012; 16 (3): R109.
21. Gu WJ, Wei CY, Yin RX. Lack of efficacy of probiotics in preventing ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. Chest. 2012; 142 (4): 859-868.